澳大拉西亚白血病与淋巴瘤协作组共识方法确认强化诱导化疗治疗急性髓系白血病的疗效与安全性
该研究前瞻性收集2018-2023年三级医院58例初治AML患者数据,评估ALLG推荐的伊达比星为基础7+3诱导±米哚妥林(按ALLG建议)的疗效与安全性。结果显示CR率88%(95%CI 77-95%),诱导死亡率1.7%(95%CI 0-9%);中位随访24.6个月,不良风险组中位OS 17.6个月 vs 非不良风险组未达到(P=0.03)。FLT3突变患者CR率89%(95%CI 67%-99%),4年EFS 65%、OS 68%,与FLT3野生型相当。58个诱导和139个巩固周期安全性可接受,诱导期间1例死亡,ICU入住率21%(95%CI 11%-33%)。
要点
- ALLG共识推荐伊达比星为基础7+3诱导(7天持续输注阿糖胞苷+三剂蒽环类)±米哚妥林,用于初治AML。
- 58例患者CR率88%(95%CI 77-95%),诱导死亡率1.7%(95%CI 0-9%)。
- 不良风险组中位OS 17.6个月 vs 非不良风险组未达到(P=0.03)。
- FLT3突变患者CR率89%(95%CI 67%-99%),4年EFS 65%、OS 68%,与FLT3野生型相当。
- 诱导期间ICU入住率21%(95%CI 11%-33%),58个诱导和139个巩固周期中仅1例死亡。
适用人群与场景
- 初治急性髓系白血病(AML)患者,前瞻性收集所有评估一线AML治疗的患者数据。
- 三级医院真实世界场景,中位年龄49岁。
诊断标准与关键阈值
- 疾病风险与缓解评估依据欧洲白血病网(European LeukaemiaNet)2017指南定义。
处置流程与药物剂量
- ALLG共识推荐:伊达比星为基础7+3诱导方案(7天持续输注阿糖胞苷+三剂蒽环类)±米哚妥林(按ALLG建议)。
- 诱导后巩固周期共139个,具体方案原文未详述。
研究设计与关键结果
- 研究类型:前瞻性真实世界研究,单中心(三级医院),2018-2023年,58例患者接受7+3诱导,中位年龄49岁。
- CR率88%(95%CI 77-95%),诱导死亡率1.7%(95%CI 0-9%)。
- 中位随访24.6个月,不良风险组中位OS 17.6个月 vs 非不良风险组未达到(P=0.03)。
- FLT3突变患者CR率89%(95%CI 67%-99%),4年EFS 65%、OS 68%,与FLT3野生型患者相当。
- 58个诱导和139个巩固周期安全性可接受,诱导期间1例死亡,ICU入住率21%(95%CI 11%-33%)。
证据类型、等级与局限
- 证据类型:前瞻性真实世界研究;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,伊达比星为基础7+3诱导联合当代支持治疗可获得良好的安全性和CR率,包括接受米哚妥林治疗的FLT3突变患者。
- 作者指出,不良风险AML患者的生存结局仍不理想。
指南或共识出处
- 澳大拉西亚白血病与淋巴瘤协作组(ALLG)共识方法;欧洲白血病网(European LeukaemiaNet)2017指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: After pharmaceutical benefits scheme approval of midostaurin for fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline) to align with future clinical trial protocols.
AIMS: To determine the efficacy and safety of idarubicin-based 7+3 induction ± midostaurin (per ALLG recommendations) in a real-world, tertiary hospital setting.
METHODS: Data were prospectively collected for all patients assessed for front-line AML treatment. Disease risk and response assessments were defined by European LeukaemiaNet 2017 guidelines. Efficacy and safety endpoints included complete remission (CR) rates, composite CR rates, event-free survival (EFS), overall survival (OS), induction mortality, duration of cytopenias and intensive care unit (ICU) utilisation. Analysis was planned following completion of ≥50 inductions and 5-year aggregated experience.
RESULTS: Between 2018 and 2023, 58 patients (median age 49 years) received 7+3 induction with CR and induction mortality rates of 88% (95% confidence interval (95% CI): 77-95%) and 1.7% (95% CI: 0-9%) respectively. At a median of 24.6 months of follow-up, median OS was 17.6 months for adverse-risk versus not reached for non-adverse-risk patients (P = 0.03). FLT3-mutated patients demonstrated an 89% CR rate (95% CI: 67%-99%) with comparable 4-year EFS (65%) and OS (68%) to FLT3-wild-type patients. Safety across 58 induction and 139 consolidation cycles was acceptable, with a single death and a 21% ICU admission rate (95% CI: 11%-33%) during induction.
CONCLUSIONS: Idarubicin-based 7+3 induction with contemporary supportive care yields good safety and CR rates, including in midostaurin-treated FLT3-mutated patients. Survival outcomes for adverse-risk AML patients remain suboptimal.
参考来源
- Tedjaseputra A, Tey A, Nalpantidis A, et al. Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach. Intern Med J. 2025. PMID: 40052282. doi:10.1111/imj.70010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。